NCT01023880终止1 期
An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy
Cephalon13 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 62
- 试验地点
- 13
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
The primary objective for part 1 of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in patients with relapsed and refractory multiple myeloma. The primary objective for part 2 is to evaluate the antitumor activity of CEP-18770 in patients treated at the MTD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has:
- •relapsed multiple myeloma that has progressed following therapies that included bortezomib and an IMiD (thalidomide or lenalidomide) either alone or in any combination.
- •multiple myeloma, which is refractory to the most recent therapy (bortezomib or IMiD, or any other chemotherapy), or the patient did not tolerate and discontinued the most recent therapy for multiple myeloma but has recovered from its toxic effects.
- •measurable disease defined as 1 of the following:
- •serum M-protein ≥0.5 g/dL
- •urine M-protein ≥200 mg/24 hours
- •a life expectancy of more than 3 months.
- •an ECOG performance status of 0, 1, or
- •adequate hepatic organ function.
- •an absolute neutrophil count (ANC), hemoglobin level, and platelet count within protocol-specific ranges.
- •been independent of granulocyte-colony stimulating factor (G-CSF) or granulocyte macrophage-colony stimulating factor (GM-CSF) support for more than 1 week.
- •been independent of platelet transfusion for more than 1 week.
- •received, or may have received, an allogeneic and/or autologous transplant.
- •a creatinine clearance of 30 mL/minute or more as measured or as calculated based on the Cockcroft-Gault method.
- •if the patient is a female of childbearing potential (not surgically sterile or 1 year postmenopausal): must use a medically accepted method of contraception (including abstinence) and must agree to continue use of this method for the duration of the study and for 3 months after participation in the study.
- •if the patient is a male: is surgically sterile, or if sexually active, is currently using an effective barrier method of contraception, and agrees to continue use of this method for the duration of the study and for 3 months after the last administration of study drug.
排除标准
- •The patient:
- •has nonmeasurable multiple myeloma.
- •received glucocorticoid therapy (prednisone >10 mg/day orally or equivalent) within the last 2 weeks prior to the first dose of study drug.
- •has POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy or monoclonal proliferative disorder, and skin changes).
- •has plasma cell leukemia.
- •received chemotherapy with approved anticancer therapeutics within 2 weeks, or within 5 drug half-lives (t1/2), or investigative anticancer therapeutics within 4 weeks, or within 5 drug half-lives (t1/2), before the first dose of study drug, whichever time is greater.
- •received radiation therapy or immunotherapy in the 4 weeks prior to, or localized radiation therapy within 1 week prior to, the first dose of study drug.
- •received prior treatment with CEP-
- •has used a medication known to be a potent inducer of CYP2E1, CYP2D6 or CYP3A4/5 within 4 weeks prior to the first dose of study drug.
- •has used a medication known to be a potent inhibitor of CYP2E1, CYP2D6 or CYP3A4/5 within 2 weeks prior to the first dose of study drug.
- •had major surgery within 3 weeks before the first dose of study drug.
- •has congestive heart failure or had symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction within the last 6 months.
- •had an acute infection requiring systemic antibiotics, antiviral agents, or antifungal agents within 2 weeks before the first dose of study drug.
- •has a known or suspected human immunodeficiency virus (HIV) infection on the basis of medical history.
- •had a nonhematologic malignancy within the past 3 years except for the following: adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or prostate cancer (Gleason grade <6 with prostate specific antigen (PSA) levels within the normal range).
- •has myelodysplastic or myeloproliferative syndrome.
- •has significant neuropathy.
- •is a pregnant or lactating woman. Any women becoming pregnant during the study will be withdrawn from the study.
- •has known central nervous system involvement.
- •has any serious psychiatric or medical condition that could interfere with treatment or study procedures, place the patient at unacceptable risk, or hinder the interpretation of study data.
- •has known hypersensitivity to mannitol or hydroxypropyl betadex.
研究组 & 干预措施
1
Experimental
CEP-18770
干预措施: CEP-18770 (Drug)
结局指标
主要结局
Overall Response Rate (ORR)
时间窗: Every 4 weeks, until completion of treatment
次要结局
- Elapsed time from the ORR date to the date of disease progression (DOR)(at disease progression)
- Elapsed time from the date of first dose of CEP-18770 to the date of first response (TTR) to treatment with CEP-18770(at date of first response (TTR) to treatment)
- Elapsed time from the date of first dose of CEP-18770 to the date of disease progression (TTP)(at date of disease progression (TTP))
研究者
研究点 (13)
Loading locations...
相似试验
已完成
1 期
Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients With Advanced CancerCancerNCT00875264Cephalon43
已完成
1 期
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid TumorsSolid TumorsNCT01922752Teva Branded Pharmaceutical Products R&D, Inc.32
已完成
1 期
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT01348919Teva Branded Pharmaceutical Products R&D, Inc.11
撤回
1 期
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)Precursor Cell Lymphoblastic Leukemia-lymphomaNCT03888534Millennium Pharmaceuticals, Inc.
已完成
1 期
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have SpreadNeoplasmsNCT04147247Boehringer Ingelheim21